Symptoms of Bacillus Calmette-Guerin Cystitis in Bladder Cancer Patients according to Tuberculosis Sequelae by Chest Radiography

키워드

참고문헌 (25)

1. Lee CH, "The burden and characteristics of tuberculosis", human immunodeficiency virus (TB, BMC Infect Dis, pp.2010, 10[DOI]
2. Yoon-Sung Park, "The National Status of Tuberculosis Using Nationwide Medical Records Survey of Patients with Tuberculosis in Korea", Tuberculosis and Respiratory Diseases, 73(1), pp.48~55 (2012), 대한결핵및호흡기학회[DOI]
3. Kim HY, "Thoracic sequelae and complications of tuberculosis", Radiographics, 21, pp.839~858 (2001)
4. Ellner JJ, "Review: the immune response in human tuberculosis--implications for tuberculosis control", J Infect Dis, 176, pp.1351~1359 (1997)
5. Jung JW, "Pulmonary impairment in tuberculosis survivors: The Korean National Health and Nutrition Examination Survey 2008-2012", PLoS One, 10, pp.e0141230~ (2015)
6. Brausi M, "A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group", J Urol, 186, pp.2158~2167 (2011)
7. van der Meijden AP, "Maintenance Bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial", Eur Urol, 44, pp.429~434 (2003)
8. Lamm DL, "Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer", J Urol, 147, pp.596~600 (1992)
9. Perez-Jacoiste Asin MA, "Bacillus Calmette-Guerin (BCG) infection following intravesical BCG administration as adjunctive therapy for bladder cancer: incidence, risk factors, and outcome in a single-institution series and review of the literature", Medicine (Baltimore), 93, pp.236~254 (2014)
10. Yeh JJ, "A high resolution computer tomography scoring system to predict culturepositive pulmonary tuberculosis in the emergency department", PLoS One, 9, pp.e93847~ (2014)
11. Babjuk M, "EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013", Eur Urol, 64, pp.639~653 (2013)
12. Oddens J, "Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guerin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance", Eur Urol, 63, pp.462~472 (2013)
13. Lamm DL, "Efficacy and safety of bacille Calmette-Guerin immunotherapy in superficial bladder cancer", Clin Infect Dis, 31(Suppl 3), pp.S86~S90 (2000)
14. Lockyer CR, "BCG immunotherapy for superficial bladder cancer", J R Soc Med, 94, pp.119~123 (2001)
15. Ratliff TL, "Intravesical Bacillus Calmette-Guerin therapy for murine bladder tumors: initiation of the response by fibronectin-mediated attachment of Bacillus Calmette-Guerin", Cancer Res, 47, pp.1762~1766 (1987)
16. Becich MJ, "Internalization of bacille Calmette-Guerin by bladder tumor cells", J Urol, 145, pp.1316~1324 (1991)
17. Lamm DL, "Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study", J Urol, 163, pp.1124~1129 (2000)
18. Sylvester RJ, "Long-term efficacy results of EORTC genitourinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guerin, and bacillus Calmette-Guerin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder", Eur Urol, 57, pp.766~773 (2010)
19. Brausi M, "Side effects of Bacillus Calmette-Guerin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genito-urinary cancers group randomised phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG", Eur Urol, 65, pp.69~76 (2014)
20. Ojea A, "A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13.5mg) versus mitomycin C", Eur Urol, 52, pp.1398~1406 (2007)
21. Colombel M, "The effect of ofloxacin on bacillus calmetteguerin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter study", J Urol, 176, pp.935~939 (2006)
22. Martinez-Piñeiro JA, "Long-term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette-Guerin with a reduced dose of 27mg in superficial bladder cancer", BJU Int, 89, pp.671~680 (2002)
23. Martinez-Piñeiro JA, "Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial", J Urol, 174, pp.1242~1247 (2005)
24. 이혜존, "The Current Status of BCG Vaccination in Young Children in South Korea", Tuberculosis and Respiratory Diseases, 72(4), pp.374~380 (2012), 대한결핵및호흡기학회[DOI]
25. Lahey T, "Mycobacterium bovis BCG and new vaccines for the prevention of tuberculosis", Microbiol Spectr (2016)[DOI]

관련 논문AI추천